Determine the necessary mass, volume, or concentration for preparing a solution.
TRC160334 - ≥95% , CAS No.1293289-69-6
AVAILABLE TO ORDER
GRADE & PURITY ≥95%
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
224,000+ research products · Triple ISO certified · COA & SDS available for every product · Same-day shipping on in-stock items
Why this grade
≥95% for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Storage & shipping
Store at -20°C Ships Ice chest + Ice pads Check lot-specific COA for exact specifications.
Quality documents
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Literature proof
Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Overview
TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury
In Vitro
TRC160334 (100~400 μΜ; 4 hours; Hep3B cells) results in dose-dependent stabilization of nuclear HIF-1. TRC160334 (75~300 μM; 4 hours; Hep3B cells) results in dose-dependent transcriptional activation of HIF-1. TRC160334 shows a dose-dependent expression of HIF target genes such as EPO and adrenomedullin. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: Hep3B cells Concentration: 100~400 μΜ Incubation Time: 4 hours Result: Resulted in dose-dependent stabilization of nuclear HIF-1.
In Vivo
TRC160334 (0.1 and 0.3 mg/kg; i.p.) significantly reduces serum creatinine and blood urea nitrogen . TRC160334 (0.3 and 0.6 mg/kg; i.p.) shows reducing trends for acute tubular necrosis . TRC160334 significantly reduces the rise in electrolyte excretion dose dependently. Preischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 6 hours while postischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 12 hours as compared with the respective vehicle control . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Sprague-Dawley male rats (250–300 g) Dosage: 0.1 and 0.3 mg/kg Administration: I.p. Result: Significantly reduced serum creatinine and blood urea nitrogen. Animal Model: Sprague-Dawley male rats (250–300 g) Dosage: 0.3 and 0.6 mg/kg Administration: I.p. Result: Showed reducing trends for acute tubular necrosis.
Form:Solid
IC50& Target:HIF hydroxylase
Specifications
Specifications & Purity
≥95%
Biochemical and Physiological Mechanisms
TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury.
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Purity
≥95%
Names and Identifiers
| Canonical Smiles | C1CCC2=C(CC1)SC3=NC(=C(C(=O)N23)C(=O)NCC(=O)O)O |
|---|---|
| Isomeric SMILES | C1CCC2=C(CC1)SC3=NC(=C(C(=O)N23)C(=O)NCC(=O)O)O |
| PubChem CID | 136008904 |
| Molecular Weight | 337.35 |
Documentation
📋 Safety Data Sheet (SDS)
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →✅ Certificate of Analysis (COA)
Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →🔬 Specification Sheet
Full quality attributes and acceptance criteria for this grade.
View spec sheet →Advanced Data
Certificates（CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Chemical and Physical Properties
| Solubility | DMSO : 25 mg/mL (74.11 mM; ultrasonic and warming and heat to 80°C) |
|---|
Solution Calculators
Reviews
Customer Reviews
Remind me later
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
Copyright © 2023–present Aladdin Scientific Corp. All rights reserved.